Literature DB >> 9515893

Acute exacerbations of chronic bronchitis: an international comparison.

P Ball1, B Make.   

Abstract

The prevalence of chronic bronchitis is between 3% and 17% in most developed countries. However, higher rates in the range of 13 to 27% are encountered in less developed areas of the world. Acute exacerbations of chronic bronchitis (AECB) have usually been defined as the presence of increases in cough/sputum, sputum purulence, and dyspnea. However, recent investigations suggest that the severity of AECB may be divided into three stages based on the history of the patient: (1) previously healthy individuals; (2) patients with chronic cough and sputum and infrequent exacerbations; and (3) persons with frequent exacerbations or more severe chronic airflow limitation. Therapy for patients with less severe AECB include older and less expensive broad-spectrum antibiotics, while newer agents are indicated for patients with the most severe stage of AECB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9515893     DOI: 10.1378/chest.113.3_supplement.199s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

Review 1.  Macrolide-resistant Streptococcus pneumoniae: clinical implications for the empiric treatment of community-acquired respiratory tract infections.

Authors:  Stephen Brunton; Paul Iannini
Journal:  MedGenMed       Date:  2005-12-07

2.  Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.

Authors:  Sanjay Sethi; John Breton; Brian Wynne
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil.

Authors:  Jose-Luis Alvarez-Sala; Peter Kardos; Jesús Martínez-Beltrán; Pilar Coronel; Lorenzo Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  Domestic biomass fuel combustion and chronic bronchitis in two rural Bolivian villages.

Authors:  R Albalak; A R Frisancho; G J Keeler
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

5.  Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project.

Authors:  Jordi Alonso; Montserrat Ferrer; Barbara Gandek; John E Ware; Neil K Aaronson; Paola Mosconi; Niels K Rasmussen; Monika Bullinger; Shunichi Fukuhara; Stein Kaasa; Alain Leplège
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

6.  Time course of recovery of health status following an infective exacerbation of chronic bronchitis.

Authors:  S Spencer; P W Jones
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 7.  Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease.

Authors:  Neil MacIntyre; Yuh Chin Huang
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 8.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Respiratory symptoms and lung function impairment in underground gold miners in ghana.

Authors:  Fy Bio; S Sadhra; C Jackson; Ps Burge
Journal:  Ghana Med J       Date:  2007-06

10.  Validity of the St George's respiratory questionnaire at acute exacerbation of chronic bronchitis: comparison with the Nottingham health profile.

Authors:  Helen Doll; Isabelle Duprat-Lomon; Erika Ammerman; Pierre-Philippe Sagnier
Journal:  Qual Life Res       Date:  2003-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.